Good health care should not be a luxury

We're on a mission to revolutionize women's health care.

We aspire to significantly enhance the quality of life and care of women by empowering patients and health care professionals with intelligent drug delivery and diagnostics. We are developing a unique platform in the field of smart therapies with a market launch planned in 2024 that has the potential to transform the way women are treated, monitored, and diagnosed.

Our supporters

How unique it is to be able to personally adjust the administration of medicine in the MedRing as a woman!!

Marlies Bongers, Prof. MD PhD

Professor, The Netherlands

It is refreshing to see novel initiatives such as the MedRing, which offers a potential paradigm shift for drug delivery and diagnostics. I expect its clinical applications will transform the treatment of women’s health.

Karolina Afors, MBBS BSc MRCOG

Consultant Obstetrician and Gynecologist, England

Having known Willem de Laat and Maarten Wiegerinck for more than 40 years, it is a privilege to endorse LiGalli. I did a lot of fertility work with them, and I am proud to be a small part of LiGalli in the future. It is impressive to see how far LiGalli has come from where it started!

Eveline Moret

Ultrasonographer specialized in fertility, The Netherlands

I have followed the development of LiGalli and the revolutionary vaginal ring, and I am extremely impressed with this innovation. This ring encapsulates the essence of modern technology, finding a solution that seamlessly fits into today’s society and empowers women.

Louise Hansen

Denmark

The MedRing’s modern, personalized approach to women’s health has the potential to dramatically shift the health of people around the world. By letting people manage their treatment in the palm of their hand, the MedRing enables people to have more power over their health and health outcomes.

Amanda Srsic, MPH

Gender & Health Researcher, United States

Meet the leadership team

Willem de Laat MD, PhD, MBA

CEO & FOUNDER Willem is the visionary father of LiGalli and acts as CEO and CTO of the company. His responsibilities are product development, partnerships, and external communication.

Godert Vinkesteijn MSc, RC

CFO Godert is a keen businessman and professional investor. He was involved in the setup of LiGalli from the early beginnings. His expertise lies in telecom and data management but also in corporate finance.

Victor Nickolson PhD

DIRECTOR PRE-CLINICAL & PHARMA Victor has researched many different molecules in his career and developed many new medications. He has a broad interest in the pharmaceutical market as well as in the technical aspects of medical devices and diagnostic principles.

Maarten Wiegerinck MD, PhD

DIRECTOR CLINICAL & SENSORING The creative mind of the company, Maarten has developed innovative devices and has believed in the diagnostical potential of the mucosal wall ever since he did his thesis work on the topic.

Martin Walraven MSc, Pharmacist

DIRECTOR OPERATIONS Martin is an experienced project manager. He spent his whole life working for various top 20-ranking international pharmaceutical companies, bringing innovative products from research to commercialization.

Barry van Amsterdam MSc

DIRECTOR BUSINESS VALUATION Barry has developed an innovative new valuation model as a certified valuation manager and has implemented it in the business case of LiGalli’s lead compound.

Thijs van Oorschot

DIRECTOR TECHNOLOGY & IT Thijs is a MedTech entrepreneur with a background in industrial design engineering, bringing extensive experience in (medical) product development, production, and quality management.

Why we care

women are underrepresented

  • Women’s health has been underrepresented in medical investment, research, and innovation.
  • Medical solutions for women have not yet been fully explored because a male-first approach has been adopted.  

We prioritize the wellbeing of women and offer personalized treatment.

exisiting solutions are challenging

  • Millions of women experience problems, side effects, and intolerability related to the current treatments.
  • Women are 50-75% more likely to have adverse reaction to medications than men.  

The vaginal wall facilitates rapid uptake of drugs and avoids the major side effects associated with swallowing a pill.

technology is outdated

  • The lack of innovation in women’s health has led to current solutions that do not adequately support women.
  • This stagnation is leading to poorer quality of life and lower health outcomes. 

The MedRing combines intelligent drug delivery and diagnostics to advance women’s health.

 

Life is complicated.

Your health care
shouldn't be.

Meet the supervisory board

Cees van den Heijkant
MBA

CHAIRMAN OF THE BOARD

Cees is a mature and senior businessman and entrepreneur as well as professional investor. Cees successfully invests in IT/tech companies, sometimes jointly with PE funds, as well as in start-ups with disruptive character.

Godert Vinkesteijn
MSc, RC

BOARD MEMBER

Godert is a keen businessman and professional investor. He was involved in the setup of LiGalli from the early beginnings. His expertise lies in telecom and data management but also in corporate finance.

Carl Thys
MSc, Pharmacist

BOARD MEMBER

Carl is Managing Partner at Eagle Rock LS. Carl developed his deep understanding of the pharmaceutical industry through various marketing and sales positions in leading corporations. His current consultancy business has only added more weight to his expertise.

We partner with the best and
most creative minds.

Our successful and diverse partnerships have leveraged ambition, innovation, and results.

Our endorsers

Prof. Douwe D. Breimer

LEIDEN UNIVERSITY, NL

PhD, Em Professor of Pharmacology

Prof. Bart CJM Fauser

UNIVERSITY OF UTRECHT, NL

MD, PhD, FRCOG, Em Professor of Reproductive Medicine

Dr. N. Geelhoed-Duijvestijn

MCH HOSPITAL, THE HAGUE, NL

Endocrinologist and expert in diabetes and glucose sensoring

Prof. Jeffrey T. Jensen

OREGON HEALTH AND SCIENCE UNIVERSITY PORTLAND, OREGON USA

MD, MPH, Depts Obs & Gynecol and Public Health and Preventive Medicine

Tjeerd Kalff

EX-CEO ORGANON PHARMACEUTICALS

Responsible for first innovative vaginal ring world wide (Nuvaring®). “That was a first generation ring, this one opens exponentially more possibilities.”

Cees van Lede

EX-CEO AKZO

“At the time I already found our vaginal ring to be one of the most beautiful and innovative products.”

Prof. Karl Malcolm

QUEEN’S UNIVERSITY OF BELFAST, N. IRE

Professor of Drug Delivery at School of Pharmacy expert in vaginal rings and animal studies

Prof. H. van der Vaart

UNIVERSITY MEDICAL CENTER UTRECHT, NL

Urogynecologist and expert in overactive bladder

Interested in collaborating?

We are looking for partners as we move our business to the market. Reach out below if you’d like to work together.

    Get in touch

    Koninginnegracht 33
    2514 AC The Hague
    The Netherlands